Richard Douglas bought $98k of ALDX
director at Aldeyra Therapeutics, Inc.. 70,000 shares at an average of $1.40, traded Mar 19, 2026, filed Mar 20, 2026.
Score components
- +15RoleDirector
- +10Trade size$98k at market
- +10Relative to holdingsHoldings up 56%
- +8Price context73% below the 52-week high
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -0.6%, 3m +8.3%, 6m -24.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-117675, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 19, 2026 | POpen-market purchase Common Stock | +70,000 | $1.40 | $98k | 195,000 | Mar 20, 2026 |
Related signals
Other insiders at Aldeyra Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 52Moderate | ALDXbuy Aldeyra Therapeutics, Inc. | Todd C Brady President and CEO | $418k 250,000 shares | +17% | |
| 41Moderate | Aldeyra Therapeutics, Inc. | Michael Alfieri Principal Financial Officer | $7,100 5,000 shares | +200% | |
| 27Weak | ALDXbuy Aldeyra Therapeutics, Inc. | Michael Alfieri Principal Financial Officer | $13k 2,500 shares | - | |
| 25Weak | ALDXsell Aldeyra Therapeutics, Inc. | Stephen Machatha Chief Development Officer | $114k 22,073 shares | -9% | |
| 47Moderate | ALDXsell Aldeyra Therapeutics, Inc. | Perceptive Advisors LLC owner | $4.8M 3,400,000 shares | -37% | |
| 23Weak | ALDXbuy Aldeyra Therapeutics, Inc. | Nancy Miller-Rich director | $10k 922 shares | - | |
| 30Weak | Aldeyra Therapeutics, Inc. | Bruce Greenberg See Remarks | $51k 10,834 shares | -8% | |
| 31Weak | Aldeyra Therapeutics, Inc. | Stephen Machatha Chief Development Officer | $76k 16,041 shares | -6% | |
| 36Weak | Aldeyra Therapeutics, Inc. | Bruce Greenberg See Remarks | $45k 13,201 shares | -9% | |
| 36Weak | Aldeyra Therapeutics, Inc. | Stephen Machatha Chief Development Officer | $37k 11,537 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.